SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
about
N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptorCannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responsesCB2 receptor-mediated migration of immune cells: it can go either wayIn vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain modelsCB2 receptors in the brain: role in central immune functionAM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitorsThe endocannabinoid system as an emerging target of pharmacotherapyThe CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetAgonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomersAM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic painEvidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonistCannabinoids as therapeutic agents in cancer: current status and future implicationsWhat we know and do not know about the cannabinoid receptor 2 (CB2)The CB2 receptor and its role as a regulator of inflammationCB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune DysregulationThe role of cannabinoids in adult neurogenesisAn optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptorsThe endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cellsPharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategiesCannabinoid receptor 1 signaling in cardiovascular regulating nuclei in the brainstem: A reviewPresynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed ratsInternational Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the ratSeparation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analoguesDifferential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptorsInvolvement of cannabinoids in the cardioprotection induced by lipopolysaccharideCannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammationCharacterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamidePresynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neuronsThe synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic painThe inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammationThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsCannabinoid receptor 2 mediates the retention of immature B cells in bone marrow sinusoidsCB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice.Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs.Loss of cannabinoid receptor CB1 induces preterm birth.hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.CB2 receptor activation inhibits melanoma cell transmigration through the blood-brain barrier.Interactions of Cannabinoids With Biochemical Substrates
P2860
Q21093349-132C071E-A84F-4A27-9663-02F5BB511FDDQ24633610-7800799F-4A71-46C9-93FC-D826C2FC76EDQ24643591-A39A1269-8474-4DD8-9243-5DF4A31CE008Q24643672-9B4E47AC-56DA-4B8B-B57E-833352187419Q24643895-AA3DEEEC-B268-47FF-A99C-C4C72DDE78F8Q24647198-B3E2034D-F9A7-491D-9425-FB47B1D5DB74Q24648473-4EBE2787-D5B7-4BED-8C98-677204FE00A7Q24650098-870FE00D-02B3-48DA-9DF3-FC3A5B523B2DQ24672356-DC6550B3-6E36-49DB-AEBB-97E9897E540FQ24673335-D1AFA129-79B8-4C19-8B56-4E643CC8278DQ24675554-07C0D0CD-DE66-495C-93A9-F7683B2FD829Q24676188-35C46B4C-ED44-4911-BAB7-00EF6E8783D4Q26866298-4C4679A4-4655-4D4D-BD58-D7C4295C3389Q27686851-51C10168-E29F-459C-A60D-86B59E30BAB7Q28066700-437AC864-9F59-4335-9DB0-0BAB7599AD8BQ28072822-C8F42BD5-DE58-440A-992A-E29FBA9B1FAFQ28085261-BBEBAEF4-51DD-4ED1-881D-1D388A80912EQ28185158-09FE4284-D642-447B-9AE5-757DCF430FC8Q28236199-123951DE-C918-4B44-9349-CBA5705F0B5DQ28241318-73ECBC63-A85B-472A-A1DC-CC703AF24503Q28257062-FA991D85-04AF-4148-9E87-6BD5127D1437Q28263081-396C5C50-4956-468B-87F0-E5C07C4304E0Q28298445-1B11CC71-116C-4CF6-90C7-664E7DAC0B1EQ28344879-A5222584-AB0F-47F1-A769-DB496FA2ACFEQ28346418-D6414B00-D4A5-470F-8358-C7F322C90F5CQ28346747-857B674C-809F-4569-AFDB-D7672F624F5FQ28349586-35C3CB01-DED5-4BE8-8A60-A379E3D7D290Q28361058-7C01A618-1B2E-4EBA-9380-4F1FC2DC28F5Q28363051-09B110F3-5D4C-4339-831F-D453445FD909Q28363375-CEA1D360-D036-4483-B292-D9A14928000EQ28366593-C05F6AA6-5954-4EB5-A6CE-B84D1973FE95Q28594581-D0EC59EC-0849-453A-8F91-A64E382EA5E4Q30486707-FCFED290-A601-40C3-914E-881B8C467629Q30491268-ABBCF208-07E7-44E4-A6C2-7D653C093D99Q30813670-A29B4B40-6BA7-458E-8D29-0D4C56B02409Q33269585-5268A7F1-FA10-4598-9783-9978D23A5AA1Q33373681-7A2D5F60-F6C5-4AD7-8588-8FE6964DE7BCQ33733994-10B3551C-742F-484A-8803-3195F75EC0CBQ33755702-F1C2792F-AD2C-4E65-9D73-DC9EF62D0E7CQ33758351-BFD6D9C5-D03A-4BCF-AF96-C89E3ECEDE7D
P2860
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
@ast
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
@en
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
@nl
type
label
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
@ast
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
@en
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
@nl
prefLabel
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
@ast
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
@en
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
@nl
P2093
P921
P1476
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor
@en
P2093
Bouaboula M
Brelière JC
Calandra B
Casellas P
P304
P407
P577
1998-02-01T00:00:00Z